Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Heike I. Grabsch et al.|The Lancet Oncology|2017Cited by 286
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam‐Hogan, R. Steele, Russell Petty et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 64